Considering the Patient in Pediatric Drug Development
How Good Intentions Turned Into Harm
Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term "children" is used...
Leider schon ausverkauft
199.99 €
versandkostenfrei
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Considering the Patient in Pediatric Drug Development “
Weitere Produktinformationen zu „Considering the Patient in Pediatric Drug Development “
Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term "children" is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term "child."
In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents.
Bibliographische Angaben
- Autor: Klaus Rose
- Verlag: Academic Press
- EAN: 9780128238882
Inhaltsverzeichnis zu „Considering the Patient in Pediatric Drug Development “
Rumpelstiltskin and the miller's daughterConclusion and outlook
Introduction
Abbreviations and technical explanations
Background
1. The process of modern drug development and the challenge of young patients
2. US and EU pediatric legislation
3. A paradigm shift
4. Introduction: specific disease areas
4.1 Tissue-engineered products (TEPs), advanced medicinal
4.2 Suicide, depression, and mental disorders in young
4.3 Cancer and malignancies in young patients
4.4 Chronic arthritis in young and adult patients, and "Juvenile Idiopathic Arthritis? (JIA)
4.5 Diabetes
4.6 Allergies and allergen-specific immunotherapy (ASIT) in young patients
4.7 Epilepsy
4.8 Multiple sclerosis
4.9 Atopic dermatitis and psoriasis
4.10 Cystic fibrosis
4.11 Vaccines and antiinfectives
5. Neonatology
6. Challenges at the interface of science, drug development, and drug approval beyond specific disease areas
6.1 The on-label/off-label framework in adults and young patients
6.2 Developmental pharmacology and the globalization of the children-are-therapeutic-orphans mantra
6.3 Extrapolation
6.4 Daily deceit in "pediatric? studies
6.5 Myths in today's medical world and "pediatric? studies
7. Juvenile animal studies
8. Child-friendly formulations: tablets, quick-dissolving formulations, liquids, and more
9. What do young patients really need?
Kommentar zu "Considering the Patient in Pediatric Drug Development"
0 Gebrauchte Artikel zu „Considering the Patient in Pediatric Drug Development“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Considering the Patient in Pediatric Drug Development".
Kommentar verfassen